Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells
FC-2.15 is a murine IgM monoclonal antibody (mAb) that recognizes a cell-surface antigen (Ag2.15) expressed in most tumor-proliferating cells of human breast carcinomas and other neoplasias. In this study the cytotoxic ability of mAb FC-2.15, its cell-surface binding properties and endocytosis in Ag...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Springer-Verlag
1995
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 10762caa a22010217a 4500 | ||
|---|---|---|---|
| 001 | PAPER-3756 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203313.0 | ||
| 008 | 190411s1995 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0029090143 | |
| 024 | 7 | |2 cas |a Antibodies, Monoclonal; Antigen-Antibody Complex; Antigens, Neoplasm; Complement, 9007-36-7 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a CIIMD | ||
| 100 | 1 | |a Ballaré, C. | |
| 245 | 1 | 0 | |a Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells |
| 260 | |b Springer-Verlag |c 1995 | ||
| 270 | 1 | 0 | |m Mordoh, J.; Instituto de Investigaciones Bioquímicas 'Fundación Campomar', Patricias Argentinas 435, 1405, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Bajorin, D., Chapman, P., Wong, G., Coit, D., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Houghton, A., Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma (1990) Cancer Res, 50, p. 7490 | ||
| 504 | |a Bover, L., Barrio, M., Slavutsky, I., Bravo, A.I., Quintans, C., Bagnati, A., Lema, B., Mordoh, J., Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor (1991) Breast Cancer Res Treat, 19, p. 47 | ||
| 504 | |a Chang, K., Pai, L., Batra, J., Pastan, I., Willingham, M., Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium (1992) Cancer Res, 52, p. 181 | ||
| 504 | |a Fogler, W., Sun, L., Klinger, M., Ghrayeb, J., Daddona, P., Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen (1989) Cancer Immunol Immunother, 30, p. 43 | ||
| 504 | |a Franker, P.J., Speck, J.C., Protein and cell membrane iodination with sparingly soluble chloramide 1,3,4,6-tetrachloro-3 a,6 a-diphenylglycouril (1978) Biochemical and Biophysical Research Communications, 80, p. 849 | ||
| 504 | |a Fujimori, K., Covell, D., Fletcher, J., Weinstein, J., Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')<inf>2</inf> and Fab in tumors (1989) Cancer Res, 49, p. 5656 | ||
| 504 | |a George, A., Spooner, R., Epenetos, A., Applications of monoclonal antibodies in clinical oncology (1994) Immunol Today, 15, p. 559 | ||
| 504 | |a Kaminski, M., Zasadny, K., Francis, I., Milik, A., Ross, C., Moon, S., Crawford, S., Wahl, R., Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody (1993) N Engl J Med, 329, p. 459 | ||
| 504 | |a LoBuglio, A., Saleh, M., Lee, J., Khazaeli, M., Carrano, R., Holden, H., Wheeler, R., Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical Aspect (1988) J Natl Cancer Inst, 80, p. 932 | ||
| 504 | |a Mordoh, J., Chacón, R., Filmus, J., Isolation of tumor cells from patients with osteosarcoma and analysis of their sensitivity to methotrexate (1981) Cancer Res, 41, p. 3621 | ||
| 504 | |a Mordoh, J., Leis, S., Bravo, A.I., Podhajcer, O.L., Ballaré, C., Capurro, M., Kairiyama, C., Bover, L., Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias (1994) Int J Biol Markers, 9, p. 125 | ||
| 504 | |a Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C (1995) A phase I clinical trial in cancer patients of a new monoclonal antibody, FC-2.15, reacting with tumor proliferating cells J Immunother (in press); Morgan, A., Sullivan, W., Graves, S., Woodhouse, C., Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2 (1989) Cancer Res, 49, p. 2773 | ||
| 504 | |a Munn, D., Cheung, N., Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma (1987) Cancer Res, 47, p. 6600 | ||
| 504 | |a Nakamura, K., Koike, M., Shitara, K., Kuwana, Y., Kiuragi, K., Igarashi, S., Hasegawa, M., Hanai, N., Chimeric anti-ganglioside G<inf>M2</inf> antibody with antitumor activity (1994) Cancer Res, 54, p. 1511 | ||
| 504 | |a Neuberger, M., Rajewsky, K., Activation of mouse complement by monoclonal mouse antibodies (1981) Eur J Immunol, 11, p. 1012 | ||
| 504 | |a Nuti, M., Turchi, V., Masci, A.M., Viacava, P., Rughetti, A., Castagna, M., Frati, L., Characterization of monoclonal antibody 436 recognizing the Arg-Pro-Ala-Pro sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells (1992) Int J Biol Markers, 7, p. 71 | ||
| 504 | |a Orlandi, R., Figini, M., Tomassetti, A., Canevari, S., Colnaghi, M.I., Characterization of a mouse-human chimeric antibody to a cancer-associated antigen (1992) Int J Cancer, 52, p. 588 | ||
| 504 | |a Press, O., Hansen, J., Farr, A., Martin, P., Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes (1988) Cancer Res, 48, p. 2249 | ||
| 504 | |a Press, O., Eary, J., Appelbaum, F., Martin, P., Badger, C., Nelp, W., Glenn, S., Bernstein, I., Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support (1993) N Engl J Med, 329, p. 1219 | ||
| 504 | |a Pricop, L., Rabinowich, H., Morel, P., Sulica, A., Whiteside, T., Herberman, R., Characterization of the Fcμ receptor of human natural killer cells (1993) J Immunol, 151, p. 3018 | ||
| 504 | |a Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Witte, J., Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma (1994) Lancet, 343, p. 1177. , the German Cancer Aid 17-1A Study Group | ||
| 504 | |a Saleh, M., Khazaeli, M., Wheeler, R., Dropcho, E., Liu, T., Urist, M., Miller, D., LoBuglio, A., Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma (1992) Cancer Res, 52, p. 4342 | ||
| 504 | |a Saleh, M., Khazaeli, M., Grizzle, W., Wheeler, R., Lawson, S., Liu, T., Russell, C., LoBuglio, A., A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer (1993) Cancer Res, 53, p. 4555 | ||
| 504 | |a Scatchard, G., The attraction of proteins for small molecules and ions (1949) Annals of the New York Academy of Sciences, 51, p. 660 | ||
| 504 | |a Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L., Hinkle, G., Siler, K., Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates (1992) Cancer Res, 52, p. 1067 | ||
| 504 | |a Soule, H.D., Vazquez, J., Long, A., Albert, S., Brennan, M., A human cell line from a pleural effusion derived from a breast carcinoma (1973) J Natl Cancer Inst, 51, p. 1409 | ||
| 504 | |a Weinstein, J.N., Eger, R.R., Covell, D.G., Black, C.D.V., Mulshine, J., Carrasquillo, J.A., Larson, S.M., Keenan, A.M., The pharmacology of monoclonal antibodies (1987) Ann NY Acad Sci, 507, p. 199 | ||
| 520 | 3 | |a FC-2.15 is a murine IgM monoclonal antibody (mAb) that recognizes a cell-surface antigen (Ag2.15) expressed in most tumor-proliferating cells of human breast carcinomas and other neoplasias. In this study the cytotoxic ability of mAb FC-2.15, its cell-surface binding properties and endocytosis in Ag2.15-expressing (Ag2.15+) cells were investigated. A51Cr-release assay was used to test the FC-2.15-mediated cytotoxicity. When human serum was used as source of complement, FC-2.15 exerted a strong cytotoxic effect against human Ag2.15+ cells such as MCF-7 (breast cancer cell line), primary breast carcinoma cells, polymorphonuclear leukocytes and chronic myeloid leukemia cells. The mAb concentration range was 1-50 μg/ml. Cytotoxicity was completely abolished when complement was inactivated. Only 3.8±2.9% of MCF-7 cells survived the treatment with FC-2.15 in the presence of human serum. A flow-cytometry assay was performed to study the Ag2.15 expression of the surviving cells and they were found to be Ag2.15-. FC-2.15 did not mediate antibody-dependent cell cytotoxicity when different effector cells were used. Scatchard analysis with125I-FC-2.15 on MCF-7 cells demonstrated an affinity constant of 6.9×107 M-1 and 2.8×106 antigenic sites/cell.125I-FC-2.15 was internalized to cytoplasmic vesicles reaching a maximum of 27% after 6 h incubation, followed by the release of labeled degradation products to the supernatant. FC-2.15 appears to exert its cytotoxic effect mainly in the presence of human complement, it reacts with intermediate affinity with a high-density surface antigen, and it is slowly internalized by Ag2.15+ cells. © 1995 Springer-Verlag. |l eng | |
| 593 | |a Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina | ||
| 593 | |a Instituto de Investigaciones Bioquímicas 'Fundación Campomar', Patricias Argentinas 435, 1405, Argentina | ||
| 690 | 1 | 0 | |a BREAST CANCER |
| 690 | 1 | 0 | |a COMPLEMENT |
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a MONOCLONAL ANTIBODY (MAB) |
| 690 | 1 | 0 | |a MONOCLONAL ANTIBODY |
| 690 | 1 | 0 | |a MONOCLONAL ANTIBODY FC 2 15 |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BREAST CANCER |
| 690 | 1 | 0 | |a CANCER CELL CULTURE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN CELL |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a ANTIBODIES, MONOCLONAL |
| 690 | 1 | 0 | |a ANTIBODY-DEPENDENT CELL CYTOTOXICITY |
| 690 | 1 | 0 | |a ANTIGEN-ANTIBODY COMPLEX |
| 690 | 1 | 0 | |a ANTIGENS, NEOPLASM |
| 690 | 1 | 0 | |a BREAST NEOPLASMS |
| 690 | 1 | 0 | |a COMPLEMENT |
| 690 | 1 | 0 | |a COMPLEMENT ACTIVATION |
| 690 | 1 | 0 | |a CYTOTOXICITY, IMMUNOLOGIC |
| 690 | 1 | 0 | |a ENDOCYTOSIS |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a IN VITRO |
| 690 | 1 | 0 | |a SUPPORT, NON-U.S. GOV'T |
| 690 | 1 | 0 | |a TUMOR CELLS, CULTURED |
| 700 | 1 | |a Barrio, M. | |
| 700 | 1 | |a Portela, P. | |
| 700 | 1 | |a Mordoh, J. | |
| 773 | 0 | |d Springer-Verlag, 1995 |g v. 41 |h pp. 15-22 |k n. 1 |p Cancer Immunol Immunother |x 03407004 |t Cancer Immunology Immunotherapy | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029090143&doi=10.1007%2fBF01788955&partnerID=40&md5=31ed1f11718bb8fb2f22e5ba12f1a40b |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1007/BF01788955 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03407004_v41_n1_p15_Ballare |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03407004_v41_n1_p15_Ballare |y Registro en la Biblioteca Digital |
| 961 | |a paper_03407004_v41_n1_p15_Ballare |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 64709 | ||